Abstract
The term "epigenetics" is defined as "heritable changes in gene expression that occur without changes in DNA sequence". Recently, it has been revealed that DNA methylation and histone modifications such as acetylation, methylation and phosphorylation are epigenetic mechanisms according to this definition. In other words, these posttranslational modifications are important factors in determining when and where a gene will be expressed. To date, several enzymes that catalyze DNA or histone modifications have been identified, such as DNA methyltransferases and histone deacetylases. Inhibitors and activators of enzymes controlling epigenetic modifications are considered useful not only as tools for the elucidation of cellular and biological phenomena, but also as therapeutic agents, since disruption of the balance of epigenetic networks is known to cause some disease states such as cancer. In this review, we present natural products and synthetic molecules that inhibit or activate enzymes catalyzing DNA methylation or histone modifications, and discuss the potential of epigenetic therapy.
Keywords: Hydrazones, Hydrazides, Hydrolysis, Isoniazid, Mycobacterium, Tuberculosis, QSAR
Current Medicinal Chemistry
Title: Epigenetic Control Using Natural Products and Synthetic Molecules
Volume: 13 Issue: 8
Author(s): T. Scior and S. J. Garces-Eisele
Affiliation:
Keywords: Hydrazones, Hydrazides, Hydrolysis, Isoniazid, Mycobacterium, Tuberculosis, QSAR
Abstract: The term "epigenetics" is defined as "heritable changes in gene expression that occur without changes in DNA sequence". Recently, it has been revealed that DNA methylation and histone modifications such as acetylation, methylation and phosphorylation are epigenetic mechanisms according to this definition. In other words, these posttranslational modifications are important factors in determining when and where a gene will be expressed. To date, several enzymes that catalyze DNA or histone modifications have been identified, such as DNA methyltransferases and histone deacetylases. Inhibitors and activators of enzymes controlling epigenetic modifications are considered useful not only as tools for the elucidation of cellular and biological phenomena, but also as therapeutic agents, since disruption of the balance of epigenetic networks is known to cause some disease states such as cancer. In this review, we present natural products and synthetic molecules that inhibit or activate enzymes catalyzing DNA methylation or histone modifications, and discuss the potential of epigenetic therapy.
Export Options
About this article
Cite this article as:
Scior T. and Garces-Eisele J. S., Epigenetic Control Using Natural Products and Synthetic Molecules, Current Medicinal Chemistry 2006; 13 (8) . https://dx.doi.org/10.2174/092986706776361067
DOI https://dx.doi.org/10.2174/092986706776361067 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Molecular Targets in Cancer Drug Discovery: Cell-Based Profiling
Current Pharmaceutical Design Dimer and Tetramer of Gallic Acid: Facile Synthesis, Antioxidant and Antiproliferative Activities
Letters in Drug Design & Discovery Synergism from Combination of Cisplatin and Multicentred Platinums Coded as DH6Cl and TH1 in the Human Ovarian Tumour Models
Medicinal Chemistry Humans Entrain to Sunlight - Impact of Social Jet Lag on Disease and Implications for Critical Illness
Current Pharmaceutical Design Perspectives for Novel Mixed Diruthenium-Organic Drugs as Metallopharmaceuticals in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Modulation of the Immune Response by Targeting Endothelial Cells
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Advances in Nanomedicine Towards Clinical Application in Oncology and Immunology
Current Pharmaceutical Biotechnology Clinical Trials Targeting Advanced Cancers by Active Immunization of T-cell Defined Tumor Antigens
Current Pharmaceutical Design CMT-3, a Non-antimicrobial Tetracycline (TC), Inhibits MT1-MMP Activity: Relevance to Cancer
Current Medicinal Chemistry Recent Progress in Research on Ribosome Inactivating Proteins
Current Protein & Peptide Science Viral and Non-Viral Methods to Genetically Modify Dendritic Cells
Current Gene Therapy Antioxidant Supplementation on Cancer Risk and During Cancer Therapy: An Update
Current Topics in Medicinal Chemistry Barminomycin, a Model for the Development of New Anthracyclines
Anti-Cancer Agents in Medicinal Chemistry Etiopathogenesis, Classical Immunotherapy and Innovative Nanotherapeutics for Inflammatory Neurological Disorders
Current Nanoscience Latest Results for Anti-Angiogenic Drugs in Cancer Treatment
Current Pharmaceutical Design Fibroblast Activation Protein in Remodeling Tissues
Current Molecular Medicine Chronic Myeloid Leukemia: Existing Therapeutic Options and Strategies to Overcome Drug Resistance
Mini-Reviews in Medicinal Chemistry Aspirin as a Chemoprevention Agent for Colorectal Cancer
Current Drug Metabolism HDAC Inhibitors as Novel Anti-Cancer Therapeutics
Recent Patents on Anti-Cancer Drug Discovery MicroRNA in Implant Dentistry: From Basic Science to Clinical Application
MicroRNA